-
Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain
Tuesday, June 27, 2023 - 11:06am | 548Read More...Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences, Inc. (NASDAQ: ARTL), presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society...
-
Artelo Biosciences Reveals Positive Pre-Clinical Results Of ART26.12, A Novel FABP5 Inhibitor, In Alleviating Chemotherapy-Induced Pain
Monday, June 27, 2022 - 10:39am | 482Read More...Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences Inc., (NASDAQ: ARTL) presented new research results entitled, “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in chemotherapy-induced pain,” during...
